Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis

Hai Wang, Miaoyun Zhao, Neetu Sud, Patricia Christian, Jing Shen, Yongyan Song, Anjeza Pashaj, Kezhong Zhang, Timothy Carr, Qiaozhu Su

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Insulin induced gene-2 (Insig-2) is an ER-resident protein that inhibits the activation of sterol regulatory element-binding proteins (SREBPs). However, cellular factors that regulate Insig-2 expression have not yet been identified. Here we reported that cyclic AMP-responsive element-binding protein H (CREBH) positively regulates mRNA and protein expression of a liver specific isoform of Insig-2, Insig-2a, which in turn hinders SREBP-1c activation and inhibits hepatic de novo lipogenesis. CREBH binds to the evolutionally conserved CRE-BP binding elements located in the enhancer region of Insig-2a and upregulates its mRNA and protein expression. Metabolic hormone glucagon and nutritional fasting activated CREBH, which upregulated expression of Insig-2a in hepatocytes and inhibited SREBP-1c activation. In contrast, genetic depletion of CREBH decreased Insig-2a expression, leading to the activation of SREBP-1c and its downstream lipogenic target enzymes. Compromising CREBH-Insig-2 signaling by siRNA interference against Insig-2 also disrupted the inhibitory effect of this signaling pathway on hepatic de novo triglyceride synthesis. These actions resulted in the accumulation of lipid droplets in hepatocytes and systemic hyperlipidemia. Our study identified CREBH as the first cellular protein that regulates Insig-2a expression. Glucagon activated the CREBH-Insig-2a signaling pathway to inhibit hepatic de novo lipogenesis and prevent the onset of hepatic steatosis and hypertriglyceridemia.

Original languageEnglish (US)
Article number32246
JournalScientific reports
Volume6
DOIs
StatePublished - Sep 1 2016

Fingerprint

Hypertriglyceridemia
Glucagon
Lipid Metabolism
Cyclic AMP
Carrier Proteins
Insulin
Sterol Regulatory Element Binding Protein 1
Liver
Genes
Lipogenesis
Hepatocytes
Proteins
Sterol Regulatory Element Binding Proteins
Messenger RNA
Hyperlipidemias
Small Interfering RNA
Fasting
Protein Isoforms
Triglycerides
Up-Regulation

ASJC Scopus subject areas

  • General

Cite this

Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling : Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. / Wang, Hai; Zhao, Miaoyun; Sud, Neetu; Christian, Patricia; Shen, Jing; Song, Yongyan; Pashaj, Anjeza; Zhang, Kezhong; Carr, Timothy; Su, Qiaozhu.

In: Scientific reports, Vol. 6, 32246, 01.09.2016.

Research output: Contribution to journalArticle

Wang, Hai ; Zhao, Miaoyun ; Sud, Neetu ; Christian, Patricia ; Shen, Jing ; Song, Yongyan ; Pashaj, Anjeza ; Zhang, Kezhong ; Carr, Timothy ; Su, Qiaozhu. / Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling : Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis. In: Scientific reports. 2016 ; Vol. 6.
@article{f7cbbce454c24b89b99771375a73d162,
title = "Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis",
abstract = "Insulin induced gene-2 (Insig-2) is an ER-resident protein that inhibits the activation of sterol regulatory element-binding proteins (SREBPs). However, cellular factors that regulate Insig-2 expression have not yet been identified. Here we reported that cyclic AMP-responsive element-binding protein H (CREBH) positively regulates mRNA and protein expression of a liver specific isoform of Insig-2, Insig-2a, which in turn hinders SREBP-1c activation and inhibits hepatic de novo lipogenesis. CREBH binds to the evolutionally conserved CRE-BP binding elements located in the enhancer region of Insig-2a and upregulates its mRNA and protein expression. Metabolic hormone glucagon and nutritional fasting activated CREBH, which upregulated expression of Insig-2a in hepatocytes and inhibited SREBP-1c activation. In contrast, genetic depletion of CREBH decreased Insig-2a expression, leading to the activation of SREBP-1c and its downstream lipogenic target enzymes. Compromising CREBH-Insig-2 signaling by siRNA interference against Insig-2 also disrupted the inhibitory effect of this signaling pathway on hepatic de novo triglyceride synthesis. These actions resulted in the accumulation of lipid droplets in hepatocytes and systemic hyperlipidemia. Our study identified CREBH as the first cellular protein that regulates Insig-2a expression. Glucagon activated the CREBH-Insig-2a signaling pathway to inhibit hepatic de novo lipogenesis and prevent the onset of hepatic steatosis and hypertriglyceridemia.",
author = "Hai Wang and Miaoyun Zhao and Neetu Sud and Patricia Christian and Jing Shen and Yongyan Song and Anjeza Pashaj and Kezhong Zhang and Timothy Carr and Qiaozhu Su",
year = "2016",
month = "9",
day = "1",
doi = "10.1038/srep32246",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling

T2 - Implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis

AU - Wang, Hai

AU - Zhao, Miaoyun

AU - Sud, Neetu

AU - Christian, Patricia

AU - Shen, Jing

AU - Song, Yongyan

AU - Pashaj, Anjeza

AU - Zhang, Kezhong

AU - Carr, Timothy

AU - Su, Qiaozhu

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Insulin induced gene-2 (Insig-2) is an ER-resident protein that inhibits the activation of sterol regulatory element-binding proteins (SREBPs). However, cellular factors that regulate Insig-2 expression have not yet been identified. Here we reported that cyclic AMP-responsive element-binding protein H (CREBH) positively regulates mRNA and protein expression of a liver specific isoform of Insig-2, Insig-2a, which in turn hinders SREBP-1c activation and inhibits hepatic de novo lipogenesis. CREBH binds to the evolutionally conserved CRE-BP binding elements located in the enhancer region of Insig-2a and upregulates its mRNA and protein expression. Metabolic hormone glucagon and nutritional fasting activated CREBH, which upregulated expression of Insig-2a in hepatocytes and inhibited SREBP-1c activation. In contrast, genetic depletion of CREBH decreased Insig-2a expression, leading to the activation of SREBP-1c and its downstream lipogenic target enzymes. Compromising CREBH-Insig-2 signaling by siRNA interference against Insig-2 also disrupted the inhibitory effect of this signaling pathway on hepatic de novo triglyceride synthesis. These actions resulted in the accumulation of lipid droplets in hepatocytes and systemic hyperlipidemia. Our study identified CREBH as the first cellular protein that regulates Insig-2a expression. Glucagon activated the CREBH-Insig-2a signaling pathway to inhibit hepatic de novo lipogenesis and prevent the onset of hepatic steatosis and hypertriglyceridemia.

AB - Insulin induced gene-2 (Insig-2) is an ER-resident protein that inhibits the activation of sterol regulatory element-binding proteins (SREBPs). However, cellular factors that regulate Insig-2 expression have not yet been identified. Here we reported that cyclic AMP-responsive element-binding protein H (CREBH) positively regulates mRNA and protein expression of a liver specific isoform of Insig-2, Insig-2a, which in turn hinders SREBP-1c activation and inhibits hepatic de novo lipogenesis. CREBH binds to the evolutionally conserved CRE-BP binding elements located in the enhancer region of Insig-2a and upregulates its mRNA and protein expression. Metabolic hormone glucagon and nutritional fasting activated CREBH, which upregulated expression of Insig-2a in hepatocytes and inhibited SREBP-1c activation. In contrast, genetic depletion of CREBH decreased Insig-2a expression, leading to the activation of SREBP-1c and its downstream lipogenic target enzymes. Compromising CREBH-Insig-2 signaling by siRNA interference against Insig-2 also disrupted the inhibitory effect of this signaling pathway on hepatic de novo triglyceride synthesis. These actions resulted in the accumulation of lipid droplets in hepatocytes and systemic hyperlipidemia. Our study identified CREBH as the first cellular protein that regulates Insig-2a expression. Glucagon activated the CREBH-Insig-2a signaling pathway to inhibit hepatic de novo lipogenesis and prevent the onset of hepatic steatosis and hypertriglyceridemia.

UR - http://www.scopus.com/inward/record.url?scp=84984918832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984918832&partnerID=8YFLogxK

U2 - 10.1038/srep32246

DO - 10.1038/srep32246

M3 - Article

C2 - 27582413

AN - SCOPUS:84984918832

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 32246

ER -